LLY

1,006.06

+1.27%↑

JNJ

209.91

+1.6%↑

ABBV

223.8

-0.55%↓

UNH

336.55

+2.68%↑

AZN

90.26

-1.28%↓

LLY

1,006.06

+1.27%↑

JNJ

209.91

+1.6%↑

ABBV

223.8

-0.55%↓

UNH

336.55

+2.68%↑

AZN

90.26

-1.28%↓

LLY

1,006.06

+1.27%↑

JNJ

209.91

+1.6%↑

ABBV

223.8

-0.55%↓

UNH

336.55

+2.68%↑

AZN

90.26

-1.28%↓

LLY

1,006.06

+1.27%↑

JNJ

209.91

+1.6%↑

ABBV

223.8

-0.55%↓

UNH

336.55

+2.68%↑

AZN

90.26

-1.28%↓

LLY

1,006.06

+1.27%↑

JNJ

209.91

+1.6%↑

ABBV

223.8

-0.55%↓

UNH

336.55

+2.68%↑

AZN

90.26

-1.28%↓

Начало・Списък с акции・Simulations Plus Inc

Simulations Plus Inc

Отворен

СекторЗдравеопазване

19.61 -0.76

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

19.39

Максимум

Ключови измерители
By Trading Economics
Приходи	67M -681K
Продажби	-2.9M 17M
P/E Средно за сектора	48.528 77.671
EPS	-0.034
Дивидентна доходност	0.48
Марж на печалбата	-3.9
Служители	212
EBITDA	327K 5.3M

Препоръки
By TipRanks
Препоръки	Купи
12-месечна прогноза	+3.54% upside

Дивиденти
By Dow Jones
Дивидентна доходност Средно за сектора	0.48% 2.35%

Пазарни показатели
By TradingEconomics
Пазарна капитализация	49M 394M
Предишно отваряне	20.37
Предишно затваряне	19.61

Настроения в новините

By Acuity

29%

71%

91 / 374 Класиране в Healthcare

Simulations Plus Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

11.12.2025 г., 23:58 ч. UTC

Придобивния, сливания и поглъщания

Destination XL to Merge With Oaktree-Backed Fullbeauty Brands -- Update

11.12.2025 г., 23:56 ч. UTC

Печалби

Costco Logs Higher Sales, Eyes Expansion to Fuel Membership Growth -- Update

11.12.2025 г., 23:03 ч. UTC

Придобивния, сливания и поглъщания

FTC Sues to Block Henkel's $725 Million Acquisition of Liquid Nails From PE Firm

11.12.2025 г., 22:06 ч. UTC

Придобивния, сливания и поглъщания

Scentre to Sell $456 Million Westfield Chermside Mall Stake to Dexus-Managed Fund

11.12.2025 г., 21:50 ч. UTC

Печалби

Costco Same-Store Sales, Membership Fees Rose in 1Q

11.12.2025 г., 23:45 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

11.12.2025 г., 23:44 ч. UTC

Пазарно говорене

Nikkei May Rise After U.S. Stock Indexes Hit Record Highs -- Market Talk

11.12.2025 г., 23:37 ч. UTC

Пазарно говорене

Gold Steady, Underpinned by Dollar's Weakness -- Market Talk

11.12.2025 г., 23:31 ч. UTC

Печалби

Broadcom Beats Revenue and Profit Forecasts as AI Chip Sales Climb -- Update

11.12.2025 г., 22:48 ч. UTC

Придобивния, сливания и поглъщания

FTC Sues to Block Henkel's $725M Acquisition of Liquid Nails From PE Firm

11.12.2025 г., 22:35 ч. UTC

Печалби

Costco Sold 4.5 Million Pies Ahead of Thanksgiving. Despite Earnings Beat, the Stock Fails to Gain Traction. -- Barrons.com

11.12.2025 г., 22:30 ч. UTC

Печалби

Broadcom Beats Earnings. The Stock Wavers After Customer Updates. -- Barrons.com

11.12.2025 г., 22:09 ч. UTC

Придобивния, сливания и поглъщания

FTC Alleges Henkel Deal Would Combine Two Biggest Brands of Construction Adhesives Sold at Stores Like Home Depot, Leading to Higher Prices

11.12.2025 г., 22:06 ч. UTC

Придобивния, сливания и поглъщания

FTC Sues to Block Henkel From Buying Loctite Competitor Liquid Nails

11.12.2025 г., 22:05 ч. UTC

Печалби

Broadcom Beats Revenue and Profit Forecasts as AI Chip Sales Climb -- Update

11.12.2025 г., 21:51 ч. UTC

Придобивния, сливания и поглъщания

Scentre to Sell $456M Westfield Chermside Mall Stake to Dexus-Managed Fund

11.12.2025 г., 21:50 ч. UTC

Пазарно говорене

Auto & Transport Roundup: Market Talk

11.12.2025 г., 21:39 ч. UTC

Печалби

Broadcom Beats Earnings. The Stock Rises. -- Barrons.com

11.12.2025 г., 21:39 ч. UTC

Печалби

Broadcom Reports $18 Billion in Revenue as AI Chip Sales Climb -- WSJ

11.12.2025 г., 21:38 ч. UTC

Печалби

Costco Tops Earnings Estimates but Stock Fails to Gain Traction -- Barrons.com

11.12.2025 г., 21:37 ч. UTC

Печалби

These Stocks Moved the Most Today: Oracle, Nvidia, Broadcom, Planet Labs, Visa, Ciena, Gemini Space Station, and More -- Barrons.com

11.12.2025 г., 21:37 ч. UTC

Пазарно говорене

Broadcom Sees AI Revenue Doubling -- Market Talk

11.12.2025 г., 21:34 ч. UTC

Придобивния, сливания и поглъщания

Scentre Will Temporarily Invest A$50M in the New Dexus Fund

11.12.2025 г., 21:29 ч. UTC

Придобивния, сливания и поглъщания

Dexus Aiming for Long-Term Holding of A$50M in Fund

11.12.2025 г., 21:28 ч. UTC

Пазарно говорене

BLS Publishing Calendar Delays Now Pushing Economic Data Into February -- Market Talk

11.12.2025 г., 21:28 ч. UTC

Придобивния, сливания и поглъщания

Dexus Expects to Introduce Additional Third-Party Equity in FY26

11.12.2025 г., 21:28 ч. UTC

Придобивния, сливания и поглъщания

Dexus: Third Party Investors to Contribute Remainder

11.12.2025 г., 21:27 ч. UTC

Придобивния, сливания и поглъщания

Dexus to Put Initial A$170M into New Dexus Strategic Investment Trust

11.12.2025 г., 21:26 ч. UTC

Придобивния, сливания и поглъщания

Scentre: Dexus Wholesale Shopping Centre Fund Already Holds 25% Stake

11.12.2025 г., 21:25 ч. UTC

Придобивния, сливания и поглъщания

Scentre: Purchase Price Represents Book Value, 5% Value Cap Rate

Сравнение с други в отрасъла

Ценова промяна

Simulations Plus Inc Прогноза

Ценова цел

By TipRanks

3.54% нагоре

12-месечна прогноза

Среден 20.5 USD 3.54%

Висок 25 USD

Нисък 16 USD

Според 5 анализатори от Wall Street, предложили 12-месечна ценова цел за Simulations Plus Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

5 ratings

Купи

Задържане

Продай

Според 5 анализатори, дали борсови рейтинги на Simulations Plus Inc през последните 3 месеца.

Настроение

By Acuity

91 / 374 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Simulations Plus Inc

Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through Software and Services segments. It also offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products. In addition, the company provides products based on mechanistic and mathematical models, such as DILIsym, NAFLDsym, ILDsym, IPFsym, RENAsym, MITOsym, and OBESITYsym products. Further, it offers Absorption, Distribution, Metabolism, Excretion, and Toxicity Predictor for chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, as well as MonolixSuite products for modeling and simulation that allows for population analyses, rapid clinical trial data analyses, and regulatory submissions. Additionally, the company provides clinical-pharmacology-based consulting services, which includes population pharmacokinetic and pharmacodynamic modeling, exposure-response analyses, clinical trial simulations, data programming, and technical writing services in support of regulatory submissions; and early drug discovery services. Furthermore, it offers creative and insightful consulting services to support its quantitative systems pharmacology and other modeling systems. The company serves pharmaceutical, biotechnology, agrochemical, cosmetics, and food industry companies, as well as academic and regulatory agencies. Simulations Plus, Inc. was incorporated in 1996 and is headquartered in Lancaster, California.